Report Description

Forecast Period

2025-2029

Market Size (2023)

USD 31.36 Billion

CAGR (2024-2029)

7.89%

Fastest Growing Segment

Diagnostics

Largest Market

     North America

Market Size (2029)

USD 48.16 Billion


Market Overview

Global Allergy Diagnostics and Therapeutics Market was valued at USD 31.36 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 7.89% through 2029. The Global Allergy Diagnostics and Therapeutics Market is a dynamic and rapidly evolving sector within the healthcare industry, aimed at diagnosing and treating allergic diseases worldwide. Allergies represent a significant health concern, affecting millions of individuals across all age groups and geographical regions. This market encompasses a wide range of diagnostic tools and therapeutic interventions designed to manage various allergic conditions, including allergic rhinitis, asthma, food allergies, eczema, and others. The market is driven by several key factors, including the rising prevalence of allergies, increasing awareness and diagnosis rates, advancements in diagnostic technologies, and the development of novel therapeutics.

One of the primary drivers of the Global Allergy Diagnostics and Therapeutics Market is the escalating prevalence of allergic diseases. Factors such as urbanization, environmental pollution, changes in lifestyle, and dietary habits have contributed to the rising incidence of allergies worldwide. As a result, there is a growing demand for accurate and efficient diagnostic methods to identify allergens and allergic triggers, driving the growth of the diagnostics segment within the market. Additionally, the increasing recognition of allergies as a significant public health issue has spurred efforts to improve access to diagnosis and treatment, further fueling market expansion.

Advancements in diagnostic technologies have played a crucial role in shaping the landscape of allergy diagnostics. Traditional methods such as skin prick tests and blood tests remain foundational tools for allergy diagnosis, but the market has witnessed the emergence of innovative technologies, including molecular diagnostics, immunoassays, and point-of-care tests. These technologies offer advantages such as greater sensitivity and specificity, faster turnaround times, and the ability to detect a broader range of allergens, thus enhancing the accuracy and efficiency of allergy diagnosis.

The therapeutics segment of the Global Allergy Diagnostics and Therapeutics Market encompasses a diverse array of treatment options aimed at managing allergic symptoms and improving patients' quality of life. Pharmacological interventions such as antihistamines, corticosteroids, leukotriene receptor antagonists, and immunomodulators form the cornerstone of allergy treatment, providing relief from symptoms such as sneezing, itching, nasal congestion, and inflammation. In recent years, there has been a growing emphasis on the development of biologic therapies targeting specific components of the immune system involved in allergic responses, offering personalized and targeted treatment approaches for patients with severe or refractory allergies.

Key Market Drivers

Rising Prevalence of Allergic Diseases

The rising prevalence of allergic diseases is a significant driver behind the growth of the Global Allergy Diagnostics and Therapeutics Market. Allergic conditions, such as allergic rhinitis, asthma, food allergies, and eczema, have become increasingly common worldwide, affecting millions of individuals across all age groups and geographical regions. Several factors contribute to this escalating prevalence, including environmental factors, changes in lifestyle, and dietary habits.

Environmental pollution, including air pollution, indoor allergens, and exposure to pollutants such as pollen and mold, plays a crucial role in triggering allergic responses. Urbanization and industrialization have led to increased levels of air pollution, exacerbating respiratory allergies such as allergic rhinitis and asthma. Similarly, indoor allergens such as dust mites, pet dander, and mold thrive in modern living environments, contributing to the development and exacerbation of allergic conditions.

Changes in lifestyle and dietary habits have also been linked to the rising prevalence of allergic diseases. Westernized diets high in processed foods, sugar, and additives have been associated with an increased risk of food allergies and sensitivities. Additionally, reduced exposure to outdoor environments and microbial diversity, often attributed to urban living and excessive hygiene practices, may contribute to the development of allergic conditions by altering immune system development and function.

The increasing prevalence of allergic diseases has led to a growing burden on healthcare systems globally, driving demand for effective diagnostic tools and therapeutic interventions. Healthcare providers are facing greater challenges in accurately diagnosing allergic conditions and implementing appropriate treatment strategies to manage symptoms and improve patients' quality of life.

In response to this growing demand, the Global Allergy Diagnostics and Therapeutics Market has witnessed significant advancements in diagnostic technologies and therapeutic options. Innovative diagnostic tools, including molecular diagnostics, immunoassays, and point-of-care tests, offer improved accuracy and efficiency in identifying allergic triggers and guiding treatment decisions. Similarly, the development of novel therapeutic modalities, such as biologic therapies and allergen immunotherapy, provides personalized and targeted treatment approaches for patients with severe or refractory allergies.

Increasing Awareness and Diagnosis Rates

The Global Allergy Diagnostics and Therapeutics Market is experiencing a significant boost from increasing awareness and diagnosis rates of allergic diseases worldwide. Awareness campaigns, education initiatives, and greater understanding among both healthcare professionals and the general population have led to heightened recognition of allergic conditions and their impact on individuals' health and well-being. One of the primary factors driving increased awareness is the growing prevalence of allergic diseases. Allergies, including allergic rhinitis, asthma, food allergies, and eczema, are becoming more common across all age groups and geographical regions. As more people experience allergic symptoms or witness them in family members or peers, there is a natural inclination to seek medical attention and explore potential causes and treatment options.

Also, the media and internet have played a crucial role in disseminating information about allergies and raising public awareness. Health-related websites, social media platforms, and online forums provide a platform for individuals to share their experiences, seek advice, and access reliable information about allergic diseases and their management. This increased accessibility to information empowers individuals to recognize and address allergic symptoms promptly, leading to earlier diagnosis and intervention.

Healthcare professionals also play a vital role in increasing awareness and facilitating timely diagnosis of allergic conditions. Continuous medical education programs, conferences, and seminars educate healthcare providers about the latest developments in allergy diagnostics and therapeutics, enabling them to accurately identify and manage allergic diseases in their patients. Additionally, guidelines and protocols for allergy diagnosis and treatment help standardize practices and ensure consistent quality of care across healthcare settings.

As awareness of allergic diseases grows, there is a corresponding increase in diagnosis rates as more individuals seek medical evaluation for their symptoms. Early diagnosis is essential for effective management of allergic conditions, as it allows for prompt initiation of appropriate treatment and preventive measures. Timely diagnosis also helps prevent complications and reduces the burden on healthcare systems by minimizing the need for emergency care and hospitalizations.

Advancements in Biotechnology and Manufacturing Processes

Advancements in diagnostic technologies are playing a pivotal role in boosting the Global Allergy Diagnostics and Therapeutics Market. These innovations are transforming the landscape of allergy diagnosis by enhancing accuracy, sensitivity, and efficiency, thereby enabling healthcare providers to effectively identify allergens and tailor treatment plans to individual patients' needs. Traditional methods of allergy diagnosis, such as skin prick tests and blood tests, remain valuable tools in clinical practice. However, advancements in diagnostic technologies have introduced a new era of precision and convenience in allergy testing. Molecular diagnostics, for instance, allow for the detection of specific genetic markers associated with allergic conditions, providing a deeper understanding of patients' immune responses, and guiding personalized treatment decisions.

Immunoassays represent another area of innovation in allergy diagnostics. These assays utilize antibodies to detect and quantify allergen-specific antibodies (IgE) in patient samples, offering high sensitivity and specificity in identifying allergic triggers. Immunoassays can be performed using various platforms, including enzyme-linked immunosorbent assays (ELISA) and fluorescent immunoassays (FIA), allowing for flexibility and scalability in allergy testing.

Point-of-care tests (POCTs) have emerged as a valuable tool for allergy diagnosis, particularly in primary care settings and remote or underserved areas. POCTs offer rapid results, often within minutes, enabling immediate identification of allergic sensitivities and facilitating timely intervention. These portable and user-friendly devices empower healthcare providers to perform allergy testing conveniently at the point of care, without the need for specialized laboratory equipment or extensive training.

The integration of digital technologies into allergy diagnostics has further expanded the capabilities of diagnostic platforms. Electronic health records (EHRs), telemedicine platforms, and mobile applications enable seamless communication and data sharing between patients and healthcare providers, facilitating remote monitoring and management of allergic diseases. Moreover, artificial intelligence (AI) and machine learning algorithms can analyze large datasets to identify patterns and correlations in allergic responses, leading to more accurate diagnosis and prediction of treatment outcomes.




Download Free Sample Report

Key Market Challenges

Underdiagnoses and Misdiagnosis

One of the primary challenges in the allergy diagnostics and therapeutics market is underdiagnosis and misdiagnosis of allergic diseases. Many individuals with allergic symptoms may not seek medical evaluation, leading to undetected cases. Moreover, misdiagnosis can occur due to overlapping symptoms with other conditions or inadequate diagnostic tools, resulting in inappropriate treatment and disease management.

Limited Access to Healthcare Services

Access to allergy diagnostics and therapeutics is not uniform globally, with disparities in healthcare infrastructure, resources, and expertise contributing to limited access in certain regions. Rural and underserved areas may lack specialized allergy clinics, diagnostic laboratories, and trained healthcare professionals, leading to delayed diagnosis and suboptimal treatment for patients with allergic diseases.

Complexity of Allergic Diseases

Allergic diseases are heterogeneous and multifactorial, presenting challenges in diagnosis and treatment. The complexity of allergic conditions, including the diverse range of allergens and underlying immunological mechanisms involved, can make accurate diagnosis and targeted therapy challenging. Additionally, comorbidities and overlapping symptoms further complicate disease management, requiring a comprehensive and individualized approach to care.

Key Market Trends

Advancements in Diagnostic Technologies

Advancements in diagnostic technologies are revolutionizing the landscape of the Global Allergy Diagnostics and Therapeutics Market. These technological innovations are enhancing the accuracy, efficiency, and accessibility of allergy diagnosis, thereby driving market growth, and improving patient outcomes. Traditional methods of allergy diagnosis, such as skin prick tests and blood tests, have been valuable tools in clinical practice. However, advancements in diagnostic technologies have introduced a new era of precision and convenience in allergy testing. Molecular diagnostics, for instance, allow for the detection of specific genetic markers associated with allergic conditions, providing insights into patients' immune responses, and guiding personalized treatment decisions.

Immunoassays represent another significant advancement in allergy diagnostics. These assays utilize antibodies to detect and quantify allergen-specific antibodies (IgE) in patient samples, offering high sensitivity and specificity in identifying allergic triggers. Immunoassays can be performed using various platforms, including enzyme-linked immunosorbent assays (ELISA) and fluorescent immunoassays (FIA), allowing for flexibility and scalability in allergy testing.

Point-of-care tests (POCTs) have emerged as a game-changer in allergy diagnosis, particularly in primary care settings and remote or underserved areas. POCTs provide rapid results, often within minutes, enabling immediate identification of allergic sensitivities and facilitating timely intervention. These portable and user-friendly devices empower healthcare providers to perform allergy testing conveniently at the point of care, without the need for specialized laboratory equipment or extensive training.

The integration of digital technologies into allergy diagnostics has further expanded the capabilities of diagnostic platforms. Electronic health records (EHRs), telemedicine platforms, and mobile applications enable seamless communication and data sharing between patients and healthcare providers, facilitating remote monitoring and management of allergic diseases. Additionally, artificial intelligence (AI) and machine learning algorithms can analyze large datasets to identify patterns and correlations in allergic responses, leading to more accurate diagnosis and prediction of treatment outcomes.

Focus on Precision Medicine

The focus on precision medicine is significantly boosting the Global Allergy Diagnostics and Therapeutics Market, transforming the landscape of allergy diagnosis and treatment. Precision medicine, also known as personalized medicine, involves tailoring medical interventions to individual patient characteristics, including genetic makeup, environmental factors, and lifestyle considerations. This approach enables healthcare providers to deliver targeted and effective treatments while minimizing adverse effects and optimizing patient outcomes. In the realm of allergy diagnostics, precision medicine has led to advancements in molecular profiling, biomarker identification, and genetic testing. These tools provide insights into patients' immune responses, allergic sensitivities, and predisposition to allergic diseases, allowing for more accurate and comprehensive allergy diagnosis. By analyzing specific genetic markers and immune signatures, healthcare providers can identify individualized allergic triggers and develop personalized treatment plans tailored to each patient's unique profile.

Precision medicine also extends to the field of allergy therapeutics, where innovative treatment approaches are being developed to target underlying disease mechanisms and pathways. Biologic therapies, for example, specifically target key mediators of allergic inflammation, offering a novel treatment option for patients with severe or refractory allergies. These biologic agents provide targeted and personalized treatment approaches, leading to improved symptom control, reduced reliance on systemic corticosteroids, and enhanced quality of life for patients with allergic diseases.

Additionally, precision medicine enables healthcare providers to optimize allergen immunotherapy (AIT), a cornerstone of allergy treatment. By identifying specific allergens to which patients are sensitized and tailoring immunotherapy formulations accordingly, precision medicine enhances treatment efficacy and safety. Personalized AIT regimens result in improved symptom relief, reduced treatment duration, and enhanced patient satisfaction, driving market growth and adoption of immunotherapy as a mainstream treatment option.

The integration of digital health technologies and artificial intelligence (AI) further enhances the precision medicine approach in allergy diagnostics and therapeutics. Electronic health records (EHRs), telemedicine platforms, and mobile applications facilitate data collection, analysis, and sharing, enabling seamless communication between patients and healthcare providers. AI algorithms analyze large datasets to identify patterns, correlations, and predictive markers in allergic responses, guiding treatment decisions and optimizing patient care. The focus on precision medicine is driving innovation, growth, and transformation in the Global Allergy Diagnostics and Therapeutics Market. By embracing personalized approaches to allergy diagnosis and treatment, healthcare providers can deliver more effective, efficient, and patient-centered care, ultimately improving outcomes and quality of life for individuals affected by allergic diseases.

Segmental Insights

Type Insights

Based on Type, Therapeutics have emerged as the dominating segment in the Global Allergy Diagnostics and Therapeutics Market in 2023. The increasing prevalence of allergic conditions globally has spurred a heightened demand for efficacious treatment options. With a growing number of individuals being diagnosed with allergies, there arises a pressing need for therapeutics capable of effectively mitigating symptoms and enhancing quality of life. Innovations in medical research and technology have paved the way for the development of more precise and effective allergy therapeutics. These advancements encompass novel formulations of drugs, biologic treatments, and immunotherapy strategies that specifically target the underlying mechanisms of allergic reactions. Healthcare providers are increasingly acknowledging the significance of personalized treatment approaches in allergy management. This shift has resulted in the adoption of tailored therapeutic protocols tailored to individual patient profiles, considering factors such as allergy type and severity, concurrent medical conditions, and treatment response.

Allergen Type Insights

Based on Allergen Type, Inhaled have emerged as the dominating segment in the Global Allergy Diagnostics and Therapeutics Market in 2023. This dominance is primarily due to the widespread prevalence of respiratory allergies triggered by inhaled allergens such as pollen, dust mites, pet dander, mold spores, and air pollutants.  Respiratory allergies, including allergic rhinitis and asthma, affect millions of individuals worldwide, contributing significantly to the overall burden of allergic diseases. Inhaled allergens are particularly pervasive in urban environments, where environmental pollution and exposure to indoor allergens are common, exacerbating allergic symptoms and respiratory conditions.


   


Download Free Sample Report

Regional Insights

Based on Region, North America have emerged as the dominating region in the Global Allergy Diagnostics and Therapeutics Market in 2023. North America boasts advanced healthcare infrastructure and a well-established healthcare system, characterized by high levels of accessibility, quality of care, and technological innovation. This facilitates early detection, accurate diagnosis, and comprehensive management of allergic diseases, driving market growth in the region.

Recent Developments

  • In October 2023, Glenmark Pharmaceuticals' subsidiary Ichnos Sciences, a clinical-stage oncology biotech, and Astria Therapeutics, a biopharmaceutical firm specializing in allergic and immunological disease therapies, announced an exclusive worldwide licensing agreement for Ichnos' OX40 antagonist monoclonal antibody portfolio. As part of the deal, Ichnos is set to receive $320 million upfront for development, regulatory, and sales milestones, accompanied by low double-digit royalties. Additionally, Ichnos agreed to provide access to its current investigational drug substance and product stocks at standardized costs to expedite development efforts.

Key Market Players

  • Thermo Fisher Scientific, Inc.
  • R-Biopharm AG
  • DASIT Group SPA
  • AGILUS DIAGNOSTICS LTD.
  • AESKU.GROUP GmbH
  • bioMérieux SA
  • Siemens Healthineers AG
  • STALLERGENES GREER International AG
  • HYCOR Biomedical, LLC 
  • Minaris Medical America, Inc.

By Type

By Allergen Type

By Test Type

By Region

  • Diagnostics
  • Therapeutics
  • Food
  • Inhaled
  • Drug
  • Other Allergens
  • Vivo Test
  • Vitro Test
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

Report Scope:

In this report, the Global Allergy Diagnostics and Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  •        Allergy Diagnostics and Therapeutics Market, By Type:

o Diagnostics

o Therapeutics

  •        Allergy Diagnostics and Therapeutics Market, By Allergen Type:

o Food

o Inhaled

o Drug

o Other Allergens

  •        Allergy Diagnostics and Therapeutics Market, By Test Type:

o Vivo Test

o Vitro Test

  • Allergy Diagnostics and Therapeutics Market, By Region:

o North America

§ United States

§ Canada

§ Mexico

o Europe

§ France

§ United Kingdom

§ Italy

§ Germany

§ Spain

o Asia Pacific

§ China

§ India

§ Japan

§ Australia

§ South Korea

o South America

§ Brazil

§ Argentina

§ Colombia

o Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

§ Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Allergy Diagnostics and Therapeutics Market.

Available Customizations:

Global Allergy Diagnostics and Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Allergy Diagnostics and Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Allergy Diagnostics and Therapeutics Market Outlook

5.1.  Market Size & Forecast

5.1.1.     By Value

5.2.  Market Share & Forecast

5.2.1.     By Type (Diagnostics, Therapeutics)

5.2.2.     By Allergen Type (Food, Inhaled, Drug, Other Allergens)

5.2.3.     By Test Type (vivo Test, vitro Test)

5.2.4.     By Region

5.2.5.     By Company (2023)

5.3.  Market Map

5.3.1.     By Type   

5.3.2.     By Allergen Type

5.3.3.     By Test Type

5.3.4.     By Region

6.    Asia Pacific Allergy Diagnostics and Therapeutics Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Type   

6.2.2.     By Allergen Type

6.2.3.     By Test Type

6.2.4.     By Country

6.3.  Asia Pacific: Country Analysis

6.3.1.     China Allergy Diagnostics and Therapeutics Market Outlook

6.3.1.1.         Market Size & Forecast

6.3.1.1.1.             By Value

6.3.1.2.         Market Share & Forecast

6.3.1.2.1.             By Type   

6.3.1.2.2.             By Allergen Type

6.3.1.2.3.             By Test Type

6.3.2.     India Allergy Diagnostics and Therapeutics Market Outlook

6.3.2.1.         Market Size & Forecast

6.3.2.1.1.             By Value

6.3.2.2.         Market Share & Forecast

6.3.2.2.1.             By Type   

6.3.2.2.2.             By Allergen Type

6.3.2.2.3.             By Test Type

6.3.3.     Australia Allergy Diagnostics and Therapeutics Market Outlook

6.3.3.1.         Market Size & Forecast

6.3.3.1.1.             By Value

6.3.3.2.         Market Share & Forecast

6.3.3.2.1.             By Type   

6.3.3.2.2.             By Allergen Type

6.3.3.2.3.             By Test Type

6.3.4.     Japan Allergy Diagnostics and Therapeutics Market Outlook

6.3.4.1.         Market Size & Forecast

6.3.4.1.1.             By Value

6.3.4.2.         Market Share & Forecast

6.3.4.2.1.             By Type   

6.3.4.2.2.             By Allergen Type

6.3.4.2.3.             By Test Type

6.3.5.     South Korea Allergy Diagnostics and Therapeutics Market Outlook

6.3.5.1.         Market Size & Forecast

6.3.5.1.1.             By Value

6.3.5.2.         Market Share & Forecast

6.3.5.2.1.             By Type   

6.3.5.2.2.             By Allergen Type

6.3.5.2.3.             By Test Type

7.    Europe Allergy Diagnostics and Therapeutics Market Outlook

7.1.  Market Size & Forecast

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Type   

7.2.2.     By Allergen Type

7.2.3.     By Test Type

7.2.4.     By Country

7.3.  Europe: Country Analysis

7.3.1.     France Allergy Diagnostics and Therapeutics Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Type   

7.3.1.2.2.             By Allergen Type

7.3.1.2.3.             By Test Type

7.3.2.     Germany Allergy Diagnostics and Therapeutics Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Type   

7.3.2.2.2.             By Allergen Type

7.3.2.2.3.             By Test Type

7.3.3.     Spain Allergy Diagnostics and Therapeutics Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Type   

7.3.3.2.2.             By Allergen Type

7.3.3.2.3.             By Test Type

7.3.4.     Italy Allergy Diagnostics and Therapeutics Market Outlook

7.3.4.1.         Market Size & Forecast

7.3.4.1.1.             By Value

7.3.4.2.         Market Share & Forecast

7.3.4.2.1.             By Type   

7.3.4.2.2.             By Allergen Type

7.3.4.2.3.             By Test Type

7.3.5.     United Kingdom Allergy Diagnostics and Therapeutics Market Outlook

7.3.5.1.         Market Size & Forecast

7.3.5.1.1.             By Value

7.3.5.2.         Market Share & Forecast

7.3.5.2.1.             By Type   

7.3.5.2.2.             By Allergen Type

7.3.5.2.3.             By Test Type

8.    North America Allergy Diagnostics and Therapeutics Market Outlook

8.1.  Market Size & Forecast

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Type   

8.2.2.     By Allergen Type

8.2.3.     By Test Type

8.2.4.     By Country

8.3.  North America: Country Analysis

8.3.1.     United States Allergy Diagnostics and Therapeutics Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Type   

8.3.1.2.2.             By Allergen Type

8.3.1.2.3.             By Test Type

8.3.2.     Mexico Allergy Diagnostics and Therapeutics Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Type   

8.3.2.2.2.             By Allergen Type

8.3.2.2.3.             By Test Type

8.3.3.     Canada Allergy Diagnostics and Therapeutics Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Type   

8.3.3.2.2.             By Allergen Type

8.3.3.2.3.             By Test Type

9.    South America Allergy Diagnostics and Therapeutics Market Outlook

9.1.  Market Size & Forecast

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Type   

9.2.2.     By Allergen Type

9.2.3.     By Test Type

9.2.4.     By Country

9.3.  South America: Country Analysis

9.3.1.     Brazil Allergy Diagnostics and Therapeutics Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Type   

9.3.1.2.2.             By Allergen Type

9.3.1.2.3.             By Test Type

9.3.2.     Argentina Allergy Diagnostics and Therapeutics Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Type   

9.3.2.2.2.             By Allergen Type

9.3.2.2.3.             By Test Type

9.3.3.     Colombia Allergy Diagnostics and Therapeutics Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Type   

9.3.3.2.2.             By Allergen Type

9.3.3.2.3.             By Test Type

10.  Middle East and Africa Allergy Diagnostics and Therapeutics Market Outlook

10.1.              Market Size & Forecast

10.1.1.   By Value

10.2.              Market Share & Forecast

10.2.1.  By Type   

10.2.2.  By Allergen Type

10.2.3.  By Test Type

10.2.4.   By Country

10.3.              MEA: Country Analysis

10.3.1.   South Africa Allergy Diagnostics and Therapeutics Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Type   

10.3.1.2.2.           By Allergen Type

10.3.1.2.3.           By Test Type

10.3.2.   Saudi Arabia Allergy Diagnostics and Therapeutics Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Type   

10.3.2.2.2.           By Allergen Type

10.3.2.2.3.           By Test Type

10.3.3.   UAE Allergy Diagnostics and Therapeutics Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Type   

10.3.3.2.2.           By Allergen Type

10.3.3.2.3.           By Test Type

10.3.4.   Egypt Allergy Diagnostics and Therapeutics Market Outlook

10.3.4.1.      Market Size & Forecast

10.3.4.1.1.           By Value

10.3.4.2.      Market Share & Forecast

10.3.4.2.1.           By Type   

10.3.4.2.2.           By Allergen Type

10.3.4.2.3.           By Test Type

11.  Market Dynamics

11.1.              Drivers

11.2.              Challenges

12.  Market Trends & Developments

12.1.              Recent Developments

12.2.              Product Launches

12.3.              Mergers & Acquisitions

13.  Global Allergy Diagnostics and Therapeutics Market: SWOT Analysis

14.  Porter’s Five Forces Analysis

14.1.              Competition in the Industry

14.2.              Potential of New Entrants

14.3.              Power of Suppliers

14.4.              Power of Customers

14.5.              Threat of Substitute Product

15.  Competitive Landscape

15.1.    Thermo Fisher Scientific, Inc.

15.1.1.           Business Overview

15.1.2.           Company Snapshot

15.1.3.           Products & Services

15.1.4.           Financials (In case of listed)

15.1.5.           Recent Developments

15.1.6.           Key Personnel Details

15.1.7.           SWOT Analysis

15.2.    R-Biopharm AG

15.3.    DASIT Group SPA

15.4.    AGILUS DIAGNOSTICS LTD.

15.5.    AESKU.GROUP GmbH

15.6.    bioMérieux SA

15.7.    Siemens Healthineers AG

15.8.    STALLERGENES GREER International AG

15.9.    HYCOR Biomedical, LLC 

15.10.  Minaris Medical America, Inc.

16.  Strategic Recommendations

17.  About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Allergy Diagnostics and Therapeutics Market was estimated to be USD 31.36 Billion in 2023.

down-arrow

Thermo Fisher Scientific, Inc., R-Biopharm AG, DASIT Group SPA were some of the key players operating in the Global Allergy Diagnostics and Therapeutics Market.

down-arrow

Underdiagnosis, cost constraints, limited access to healthcare, regulatory hurdles, and the complexity of allergic diseases signifies a major challenge for the Global Allergy Diagnostics and Therapeutics Market.

down-arrow

Rising prevalence advancements in diagnostic technologies, focus on precision medicine, increasing awareness, and expanding therapeutic options are major factors boosting the Global Allergy Diagnostics and Therapeutics Market.

profile

Sakshi Bajaal

Business Consultant
Press Release

Allergy Diagnostics and Therapeutics Market to Grow with a CAGR of 7.89% through 2029

Jun, 2024

Advancements in diagnostic technologies is expected to drive the Global Allergy Diagnostics and Therapeutics Market growth in the forecast period, 2025-2029.